These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 26661725

  • 21. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality.
    Chakrabarti S, Lees A, Jones SG, Milligan DW.
    Bone Marrow Transplant; 2000 Oct; 26(8):871-6. PubMed ID: 11081387
    [Abstract] [Full Text] [Related]

  • 22. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis.
    Vehreschild MJ, Weitershagen D, Biehl LM, Tacke D, Waldschmidt D, Töx U, Wisplinghoff H, Von Bergwelt-Baildon M, Cornely OA, Vehreschild JJ.
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):823-8. PubMed ID: 24607558
    [Abstract] [Full Text] [Related]

  • 23. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T, Van Matre AG, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, Benamu E, Kaiser JN, Barber GR, Chase S, Tobin J, Fish DN, Gutman JA.
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [Abstract] [Full Text] [Related]

  • 24. Postoperative antimicrobials after lung transplantation and the development of multidrug-resistant bacterial and Clostridium difficile infections: an analysis of 500 non-cystic fibrosis lung transplant patients.
    Whiddon AR, Dawson KL, Fuentes A, Perez KK, Peterson LE, Kaleekal T.
    Clin Transplant; 2016 Jul; 30(7):767-73. PubMed ID: 27091109
    [Abstract] [Full Text] [Related]

  • 25. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP, Cornetta K, Fausel CA, Farag SS.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [Abstract] [Full Text] [Related]

  • 26. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection.
    Rodriguez S, Hernandez MB, Tarchini G, Zaleski M, Vatanchi M, Cardona L, Castro-Pavia F, Schneider A.
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1856-61. PubMed ID: 24681079
    [Abstract] [Full Text] [Related]

  • 27. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.
    Mani S, Rybicki L, Jagadeesh D, Mossad SB.
    Bone Marrow Transplant; 2016 May; 51(5):713-7. PubMed ID: 26726944
    [Abstract] [Full Text] [Related]

  • 28. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation.
    Bruminhent J, Wang ZX, Hu C, Wagner J, Sunday R, Bobik B, Hegarty S, Keith S, Alpdogan S, Carabasi M, Filicko-O'Hara J, Flomenberg N, Kasner M, Outschoorn UM, Weiss M, Flomenberg P.
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1329-34. PubMed ID: 24792871
    [Abstract] [Full Text] [Related]

  • 29. Pediatric oncology and stem cell transplant patients with healthcare-associated Clostridium difficile infection were already colonized on admission.
    Al-Rawahi GN, Al-Najjar A, McDonald R, Deyell RJ, Golding GR, Brant R, Tilley P, Thomas E, Rassekh SR, O'Gorman A, Wong P, Turnham L, Dobson S.
    Pediatr Blood Cancer; 2019 May; 66(5):e27604. PubMed ID: 30666782
    [Abstract] [Full Text] [Related]

  • 30. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 31. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF.
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [Abstract] [Full Text] [Related]

  • 32. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
    Yeh AC, Brunner AM, Spitzer TR, Chen YB, Coughlin E, McAfee S, Ballen K, Attar E, Caron M, Preffer FI, Yeap BY, Dey BR.
    Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
    [Abstract] [Full Text] [Related]

  • 33. Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation.
    Kinnebrew MA, Lee YJ, Jenq RR, Lipuma L, Littmann ER, Gobourne A, No D, van den Brink M, Pamer EG, Taur Y.
    PLoS One; 2014 May; 9(3):e90158. PubMed ID: 24662889
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients.
    Krishna SG, Zhao W, Apewokin SK, Krishna K, Chepyala P, Anaissie EJ.
    Transpl Infect Dis; 2013 Oct; 15(5):493-501. PubMed ID: 24034141
    [Abstract] [Full Text] [Related]

  • 37. Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains.
    Jain T, Croswell C, Urday-Cornejo V, Awali R, Cutright J, Salimnia H, Reddy Banavasi HV, Liubakka A, Lephart P, Chopra T, Revankar SG, Chandrasekar P, Alangaden G.
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):157-63. PubMed ID: 26211988
    [Abstract] [Full Text] [Related]

  • 38. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Varaldo R, Ghiso A, Gobbi M, Carella AM, Signori A, Galaverna F, Bacigalupo A.
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [Abstract] [Full Text] [Related]

  • 39. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D, DeFor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D.
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [Abstract] [Full Text] [Related]

  • 40. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.